文献速递抗栓抗凝管理特殊人群用药

优化住院患者直接口服抗凝药治疗的改良德尔菲研究

Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants: a single-centre modified Delphi study.
PubMed 文献 · Br J Clin Pharmacol · 2024-07-03

该研究在比利时一家1000床大学医院开展两步改良德尔菲研究,两个专家小组各完成两轮问卷,更新围手术期DOAC管理本地指南并制定非手术住院患者DOAC暂停管理指南。两指南针对识别出的场景给出清晰的抗凝治疗策略,旨在支持处方医生并促进医院药师开展针对性处方审核。

要点

  • 围手术期指南纳入延迟术后恢复DOAC的原因,如无法口服、3天内可能再次干预、止血不充分。
  • 非手术住院患者指南列出中断DOAC治疗的可能原因,并对应给出抗凝策略。
  • 指南目标为支持处方者并增强医院药师针对性处方审核。

核心结论

  • 研究更新并制定了住院手术与非手术患者的DOAC管理指南,旨在支持处方医生并增强医院药师的针对性处方审核。

研究设计与样本

  • 在比利时一家1000床大学医院开展两步改良德尔菲研究,设围手术期与非手术患者两个专家小组,各完成两轮(先个体在线轮,后面对面小组会议)。
  • 德尔菲问卷基于文献综述和处方者电话调查开发。

主要发现

  • 两轮德尔菲流程后,更新版围手术期DOAC管理指南纳入延迟术后恢复DOAC的原因,包括无法口服、3天内可能再次干预、止血不充分(如活动性临床显著血肿、出血引流或伤口)。
  • 同时制定了非手术住院患者指南,列出中断DOAC治疗的可能原因,两指南均针对识别场景给出清晰抗凝策略。

临床怎么用

  • 医院药师可依据两指南对围手术期及非手术住院DOAC患者进行针对性处方审核,识别延迟恢复或中断治疗的适用场景。

局限性

  • 单中心研究,仅在一家比利时大学医院开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The management of patients treated with direct oral anticoagulants (DOACs) during hospitalization is a common challenge in clinical practice. Although bridging is generally not recommended, too often DOACs are switched to parenteral therapy with low molecular weight heparins. Our objectives were to update a local guideline for perioperative DOAC management and to develop a guideline for the anticoagulation management in non-surgical patients regarding temporary DOAC discontinuation. METHODS: We executed a two-step modified Delphi study in a 1000-bed university hospital in Belgium. The Delphi questionnaires were developed based on a literature review and a telephone survey of prescribers. Two expert panels were established: one dedicated to perioperative DOAC management and the other to DOAC management in non-surgical patients. Both panels completed two rounds, commencing with an individual and online round, followed by a face-to-face group session. RESULTS: After the two-round Delphi process, the updated perioperative guideline on DOAC management included reasons for delaying the resumption of DOACs following surgery, such as oral intake not possible, the probability of re-intervention within 3 days, and insufficient haemostasis (e.g. active clinically significant haematoma, haemorrhagic drains or wounds). Furthermore, a guideline for non-surgical hospitalized patients was developed, outlining possible reasons for interrupting DOAC therapy. Both guidelines offer clear anticoagulation therapy strategies corresponding to the identified scenarios. CONCLUSIONS: We have updated and developed guidelines for DOAC management in surgical and non-surgical patients during hospitalization, which aim to support prescribers and to enhance targeted prescription review by hospital pharmacists.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Capiau A, De Vleeschauwer J, De Backer T, et al. Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants: a single-centre modified Delphi study. Br J Clin Pharmacol. 2024. PMID: 38957976. doi:10.1111/bcp.16159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。